Education
About Us
Working with TipRanks
Follow Us
Kiniksa Pharmaceuticals Ltd. Class A (KNSA)
:KNSA
KNSA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$16.56 - $28.15
Previous CloseN/A
Volume84.12K
Average Volume (3M)685.72K
Market Cap
$1.40B
Enterprise Value$1.20B
Total Cash (Recent Filing)-$55.97M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.73
Next Earnings
May 06, 2025EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding42,009,500
10 Day Avg. Volume688,988
30 Day Avg. Volume685,721
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.01
Price to Cash Flow (P/CF)22.60
P/FCF Ratio22.80
Enterprise Value/Market Cap0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.83
Enterprise Value/Ebitda-27.00
Forecast
1Y Price Target
$34.25Price Target Upside65.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Kiniksa Pharmaceuticals News
PremiumCompany Announcements
Kiniksa Pharmaceuticals Reports Strong Growth Amid Challenges
PremiumCompany Announcements
Kiniksa Pharmaceuticals Reports Strong ARCALYST Growth
PremiumCompany Announcements
Kiniksa Pharmaceuticals Ends License Agreement with MedImmune
---
Bulls Say, Bears Say
Bulls Say
Financial HealthKiniksa Pharmaceuticals ended the year with $243.6 million of cash and equivalents and expects to be cash flow positive while funding clinical trials, indicating strong financial health.
Market Share GrowthArcalyst market share should continue to grow in earlier lines of treatment, with encouraging trends in expected utilization in 1st and 2nd recurrence points.
Revenue Growth PotentialThe increase in patient restarts could be a source of revenue growth as these numbers continue to increase.
Bears Say
Lack Of Clinical CatalystsThe lack of clinical catalysts in 2025 means Arcalyst will be the main driver of the stock in the near term.
Limited Treatment Duration GrowthAverage upside looks limited on treatment duration, despite some room for growth.
Strategic DiscontinuationThe company announced the discontinuation of its abiprubart development plans in Sjögren’s disease, which is viewed as a rational decision given the competitive landscape.
---
Ownership Overview
7.81% Insiders
19.28% Mutual Funds
45.62% Other Institutional Investors
13.84% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KNSA FAQ
What was Kiniksa Pharmaceuticals Ltd. Class A’s price range in the past 12 months?
Kiniksa Pharmaceuticals Ltd. Class A lowest stock price was $16.56 and its highest was $28.15 in the past 12 months.
What is Kiniksa Pharmaceuticals Ltd. Class A’s market cap?
Kiniksa Pharmaceuticals Ltd. Class A’s market cap is $1.40B.
When is Kiniksa Pharmaceuticals Ltd. Class A’s upcoming earnings report date?
Kiniksa Pharmaceuticals Ltd. Class A’s upcoming earnings report date is May 06, 2025 which is in 21 days.
How were Kiniksa Pharmaceuticals Ltd. Class A’s earnings last quarter?
Kiniksa Pharmaceuticals Ltd. Class A released its earnings results on Feb 25, 2025. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of $0.024 by -$0.144.
Is Kiniksa Pharmaceuticals Ltd. Class A overvalued?
According to Wall Street analysts Kiniksa Pharmaceuticals Ltd. Class A’s price is currently Undervalued.
Does Kiniksa Pharmaceuticals Ltd. Class A pay dividends?
Kiniksa Pharmaceuticals Ltd. Class A does not currently pay dividends.
What is Kiniksa Pharmaceuticals Ltd. Class A’s EPS estimate?
Kiniksa Pharmaceuticals Ltd. Class A’s EPS estimate is 0.02.
How many shares outstanding does Kiniksa Pharmaceuticals Ltd. Class A have?
Kiniksa Pharmaceuticals Ltd. Class A has 42,009,500 shares outstanding.
What happened to Kiniksa Pharmaceuticals Ltd. Class A’s price movement after its last earnings report?
Kiniksa Pharmaceuticals Ltd. Class A reported an EPS of -$0.12 in its last earnings report, missing expectations of $0.024. Following the earnings report the stock price went up 0.458%.
Which hedge fund is a major shareholder of Kiniksa Pharmaceuticals Ltd. Class A?
Currently, no hedge funds are holding shares in KNSA
---
Kiniksa Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.25 (65.54% Upside)
$34.25 (65.54% Upside)
Blogger Sentiment
Bullish
KNSA Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
19.66%
12-Months-Change
Fundamentals
Return on Equity
-9.85%
Trailing 12-Months
Asset Growth
10.30%
Trailing 12-Months
Company Description
Kiniksa Pharmaceuticals Ltd. Class A
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
---
KNSA Company Deck
---
KNSA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth and development progress, particularly with ARCALYST and the new KPL-387 program. However, the call also noted some challenges, including a net loss for the year and the discontinuation of abiprubart development. Despite these challenges, the company's strong financial position and future growth prospects offer a positive outlook.Read More>---
KNSA Stock 12 Month Forecast
Average Price Target
$34.25
▲(65.54% Upside)
Technical Analysis
Best Analysts Covering KNSA
1 Year
1 Year Success Rate
8/13 ratings generated profit
1 Year Average Return
+10.51%
reiterated a buy rating 2 months ago
Copying Paul Choi's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +10.51% per trade.
---